Nevirapine: new preparation.  In second-line triple-drug anti-HIV regimens.
(1) Nevirapine is the first non nucleoside inhibitor of HIV-1 reverse transcriptase to be marketed in France. (2) The clinical file comprises three comparative double-blind trials.  One showed a better clinical benefit (in terms of disease progression or death) of a three-drug regimen comprising zidovudine, didanosine and nevirapine than with zidovudine + didanosine bitherapy.  Two trials focusing on laboratory criteria (viral load and the CD4+ cell count) showed that a three-drug regimen of zidovudine + didanosine + nevirapine was more effective, after 12 months of treatment, than bitherapy with zidovudine + nevirapine or zidovudine + didanosine. (3) Occasionally severe cutaneous reactions are the main adverse effects of nevirapine. (4) Nevirapine is a liver enzyme inducer, hence the possibility of drug interactions, especially with protease inhibitors of HIV; the clinical consequences are poorly known.
D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019829:Nevirapine / Q000009:adverse effects / Q000627:therapeutic use; D009705:Nucleosides / Q000493:pharmacokinetics; D011480:Protease Inhibitors / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D004338:Drug Combinations; D009705:Nucleosides; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine